# Regeneron Pharmaceuticals, Inc. (REGN) — Q3-2015 Earnings Results

**Report date:** 2015-11-04 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q3-2015

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Down 2.42%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.47 | N/A | +32.70% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Management expressed confidence in the company's product pipeline and future growth. They acknowledged the competitive landscape but remained focused on innovation.

**Key quotes:**

> Management highlighted strong performance in key product areas.

> They noted ongoing investments in research and development.

> There was an emphasis on maintaining market leadership.

### Guidance Changes

No guidance updates were provided during the earnings call.

### What It Means

Regeneron's strong EPS performance indicates better-than-expected profitability, but the stock's decline of 2.42% suggests investor concerns about future revenue growth or market conditions. The lack of revenue data and guidance may have contributed to cautious sentiment among investors. Overall, while the earnings beat is positive, uncertainty remains regarding the company's future performance.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q3-2015_